Advertisement

Topics

PubMed Journals Articles About "Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin" RSS

23:52 EDT 24th May 2018 | BioPortfolio

Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin articles that have been published worldwide.

More Information about "Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin" on BioPortfolio

We have published hundreds of Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin news stories on BioPortfolio along with dozens of Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin Clinical Trials and PubMed Articles about Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin Companies in our database. You can also find out about relevant Phase 3 Study Of Tavocept Vs Placebo In Patients With Newly Diagnosed Or Relapsed Advanced Primary Adenocarcinoma Of The Lung Treated With Docetaxel Or Paclitaxel Plus Cisplatin Drugs and Medications on this site too.

Showing "Phase Study Tavocept Placebo Patients With Newly Diagnosed" PubMed Articles 1–25 of 85,000+

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.

This Phase II study was designed to determine the efficacy of the mTOR inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma.


Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus: An Observational Cohort study.

To reveal the prevalence of Diabetes Mellitus (DM) in patients with newly diagnosed Rheumatoid Arthritis (RA) and evaluate the association between clinical characteristics of RA and DM as well as treatment response in newly diagnosed RA patients with DM.

Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686.

ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and FLAIR-hyperintense tumor assessed by central reading prognosticate overall survival (OS).


Circulating LECT2 levels in newly diagnosed type 2 diabetes mellitus and their association with metabolic parameters: An observational study.

Leukocyte cell-derived chemotaxin 2 (LECT2) is a hepatokine expressed in hepatocytes and appears to be involved in energy metabolism. The aim of this study was to determine plasma LECT2 levels in newly diagnosed type 2 diabetic patients and to correlate the results with various metabolic parameters.A total of 93 newly diagnosed type 2 diabetic patients and 80 age- and sex-matched nondiabetes mellitus ones were enrolled in the study. Plasma LECT2 levels were measured by enzyme-linked immunosorbent assay.Circ...

Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.

In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM).

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

Purpose Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias. Methods CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients < 18 years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-...

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal data suggest that lower doses may be as effective and less toxic. The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.

Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.

Vorinostat, a histone deacetylase inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.

A feasibility study on using tablet personal computers for self-reported symptom assessment in newly diagnosed lung cancer patients.

The study aimed to assess the feasibility and acceptability of an innovative tablet-assisted self-reported symptom assessment among newly diagnosed lung cancer patients.

A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome.

POEMS syndrome is a rare plasma dyscrasia without standard treatment. This phase II prospective trial evaluates the safety and response of 12 cycles of low dose lenalidomide (10mg) plus dexamethasone (Rdex) in patients with newly diagnosed POEMS syndrome. Forty-one patients (28 men) were enrolled and the median age at diagnosis was 49 years (range, 21-70 years). Twenty-one patients (46%) achieved complete hematologic response and the neurologic response rate was 95%. The median serum VEGF declined from 5155...

Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma.

Newly diagnosed elderly patients (age > 65-70 years) with glioblastoma should be treated with a patient-centred approach by a multi-disciplinary team. Chronological age alone should not be considered as a contraindication to treatment with maximal safe surgical resection. A 3-week course of adjuvant radiation and chemotherapy is appropriate in selected elderly patients with favourable Karnofsky performance status (KPS) who cannot tolerate a longer 6-week course of fractionated radiotherapy. The presence ...

Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

Androgen deprivation therapy (ADT) has been conventional treatment of newly diagnosed metastatic prostate cancer for more than 70 years. However, all patients eventually become castration-resistant and a significant proportion of life span is spent in the castration-resistant state. Prospective randomized control trials have incorporated early chemotherapy along with ADT based on the hypothesis that a significant level of resistance to ADT already exists in newly diagnosed metastatic prostate cancer and AD...

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models. In a phase I study for newly diagnosed GBM after chemoradiotherapy, we have previously reported our initial dose-escalation results combining disulfiram with adjuvant temozolomide and established the maximum tolerated dose (MTD) as 500 mg per day. Here we report the final results of the phase I study including an additional dose-expansion cohort of disul...

Asthma control and adherence in newly diagnosed young and elderly adult patients with asthma in Turkey.

This study aimed to evaluate the factors that affect asthma control and adherence to treatment in newly diagnosed elderly asthmatics in Turkey compared with younger patients.

The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase.

Objective: To compare the clinical efficacy and safety of nilotinib and imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase(CML-CP). Methods: Until December 31st 2016, 18 patients using nilotinib and 83 using imatinib were recruited in our study. The efficacy and safety of two groups were evaluated. Results: A total of 101 patients with CML-CP included 18 receiving nilotinib and 83 imatinib. The optimal response rates at 3, 6, 12 and 18 months in nilotini...

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.

To investigate evolving patterns in antithrombotic treatment in UK patients with newly diagnosed non-valvular atrial fibrillation (AF).

Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for Ascaris Lumbricoides and Trichuris Trichiura Infection Treatment in Pediatric Patients: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study.

This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of a new chewable, rapidly-disintegrating mebendazole (MBZ) 500 mg tablet for Ascaris lumbricoides and Trichuris trichiura infection treatment. Pediatric patients (1-15 years; N = 295; from Ethiopia and Rwanda) excreting A. lumbricoides and/or T. trichiura eggs were enrolled. The study had a screening phase (3 days), a double-blind treatment phase (DBP, 19 days), and an open-label phase (OLP, 7 days). Patients received...

Markers influencing the presence of partial clinical remission in patients with newly diagnosed type 1 diabetes.

The aim of the study was to compare the selected markers in children with and without partial clinical remission (CR) of newly diagnosed type 1 diabetes (T1D).

Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors.

Medical staff often overlook or underestimate the presence or severity of cognitive dysfunction. The purpose of this study was to clarify the frequency, clinical indicators and predictors of cognitive dysfunction among newly diagnosed older patients with hematologic malignancy receiving first-line chemotherapy.

HIV-1 transmission networks across Cyprus (2010-2012).

A molecular epidemiology study of HIV-1 infection was conducted in one hundred diagnosed and untreated HIV-1-infected patients in Cyprus between 2010 and 2012, representing 65.4% of all the reported HIV-1 infections in Cyprus in this three-year period, using a previously defined enrolment strategy. Eighty-two patients were newly diagnosed (genotypic drug resistance testing within six months from diagnosis), and eighteen patients were HIV-1 diagnosed for a longer period or the diagnosis date was unknown. Phy...

Advantages and disadvantages of combined chemotherapy with carmustine wafer and bevacizumab in patients with newly diagnosed glioblastoma: A single institutional experience.

To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM).

Prognosis of ischaemic heart disease in patients with newly diagnosed dm type 2 by logistic regression.

Introduction: Diabetes Mellitus (DM) type 2 is an important medical and social problem all around the world. One of the most serious and widespread complications of DM type 2 is a damage to the cardiovascular system. The aim was to study the way of how to predict the IHD development in patients with the newly diagnosed DM type 2 by building a mathematical model with the help of statistical method, in particular, a logistic regression, which allows predicting the occurrence of IHD by the levels of proven bio...

Histone Modification Patterns using RPPA-based Profiling Predict Outcome in Acute Myeloid Leukemia Patients.

Post-translational histone tail modifications are known to play a role in leukemogenesis and are therapeutic targets. A global analysis of the level and patterns of expression of multiple histone modifying proteins (HMP) in acute myeloid leukemia (AML) and the effect of different patterns of expression on outcome and prognosis has not been investigated in AML patients. Here we analyzed 20 HMP by reverse phase protein array (RPPA) in a cohort of 205 newly diagnosed AML patients. Protein levels were correlate...

Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic phase chronic myeloid leukemia.

This multicenter cooperative study aimed to analyze the adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) used as initial treatment for chronic-phase chronic myeloid leukemia (CML-CP) and their impact on outcome.


Advertisement
Quick Search
Advertisement
Advertisement